Relationship Between Cisplatin Administration and the Development of Ototoxicity

2006 ◽  
Vol 24 (6) ◽  
pp. 918-924 ◽  
Author(s):  
Jeany M. Rademaker-Lakhai ◽  
Mirjam Crul ◽  
Lot Zuur ◽  
Paul Baas ◽  
Jos H. Beijnen ◽  
...  
Keyword(s):  
Hearing Loss ◽  
Small Cell Lung Carcinoma ◽  
Area Under The Curve ◽  
Dose Intensity ◽  
Cell Lung Carcinoma ◽  
High Frequencies ◽  
Hearing Thresholds ◽  
Receive Treatment ◽  
To Receive

Purpose To determine the auditory toxicity associated with dose- and schedule- intensive cisplatin/gemcitabine chemotherapy in non–small-cell lung carcinoma patients. Patients and Methods Patients were treated with gemcitabine followed by cisplatin according to an interpatient dose-escalation scheme. Patients were randomly assigned to receive treatment once a week for 6 weeks or once every 2 weeks for 4 weeks. The following cohorts of patients were treated with a reversed schedule once every 2 weeks, in which cisplatin was followed by gemcitabine. The dose-intensity of cisplatin was equal in both schedules. Audiometric evaluations were obtained for each ear at several frequencies. Mean hearing loss after cisplatin treatment was computed for each dose level at each tested frequency in each ear at baseline and subsequent follow-up audiometry. Pure tone averages (PTAs) were also calculated. The pharmacokinetics of cisplatin was determined to study the correlation among the maximum drug concentration, the area under the curve of unbound platinum, and the development of ototoxicity. Results A total of 328 audiograms were analyzed. At the higher frequencies, a more severe hearing impairment was recorded. Most patients showed a decrease in hearing thresholds at dosages above 60 mg/m2 cisplatin at the higher frequencies. PTAs at 1, 2, and 4 kHz show a mean hearing loss of 19 dB after cisplatin administration at dosages above 90 mg/m2. Threshold shifts at 8 and 12.5 kHz after cisplatin administration were experienced at dosages above 60 mg/m2. Conclusion Hearing loss after cisplatin therapy occurs mainly at high frequencies and at cisplatin dosages more than 60 mg/m2. It is more pronounced when cisplatin is given once every 2 weeks.

scholarly journals Estimation of auditory threshold in an extended frequency range in elderly people

2019 ◽  
Vol 4 (4) ◽  
pp. 4-7
Author(s):  
Lubov V. Aizenshtadt ◽  
Tatyana Yu. Vladimirova ◽  
Alexandr V. Kurenkov ◽  
Anastasia M. Kashapova
Keyword(s):  
Hearing Loss ◽  
Age Group ◽  
Auditory Function ◽  
Frequency Range ◽  
Auditory Thresholds ◽  
High Frequencies ◽  
Age Related ◽  
Hearing Thresholds ◽  
Extended Frequency Range ◽  
Extended Frequency

Objectives - to study hearing thresholds at high frequencies in elderly and senile patients, taking into account the age norm and the presence of comorbid diseases. Material and methods. 111 patients aged from 50 to 97 years (mean age 70.5 ± 2.1) were examined, their age, auditory function, and concomitant diseases were also registered. Results. The measured average auditory thresholds at high frequencies, if compared to the age-related standards for auditory sensitivity, have revealed an underestimated hearing loss in 12.6% of patients. The presence of concomitant diseases has a significant impact on the development of chronic sensorineural hearing loss in each age group. Conclusion. Audiometry in an extended frequency range in elderly patients with concurrent diseases can improve the hearing examination algorithm.

scholarly journals Progression of Hearing Loss in the Aging Population: Repeated Auditory Measurements in the Rotterdam Study

2018 ◽  
Vol 23 (5) ◽  
pp. 290-297 ◽  
Author(s):  
Stephanie C. Rigters ◽  
Marc P. van der Schroeff ◽  
Grigorios Papageorgiou ◽  
Robert J. Baatenburg de Jong ◽  
André Goedegebure
Keyword(s):  
Type 2 Diabetes ◽  
Hearing Loss ◽  
Sex Education ◽  
Estimating Equation ◽  
Cholesterol Ratio ◽  
Speech In Noise ◽  
Hearing Thresholds ◽  
Aging Adults

We quantified changes in the auditory acuity of 675 aging adults (mean age 71.1 years, 52.0% female, mean follow-up 4.4 years ± 0.2) of an ongoing cohort study with a pure-tone audiogram and a speech-in-noise test. Generalized estimating equation models were used to study the association between hearing loss and the progression with age, sex, education, cognition, BMI, blood pressure, having type 2 diabetes mellitus, cholesterol ratio, smoking and alcohol consumption. The mean progression of hearing loss was 0.29 and 1.35 dB/year (low and high frequencies). Progression of hearing loss was associated with baseline hearing thresholds. Besides, the presence of type 2 diabetes, smoking, age, sex and time were associated with worse hearing at baseline, but there was no statistical evidence that the tested determinants were associated with progression of hearing loss. This finding indicates that the 4-year progression of hearing loss in older adults in this study is not influenced by the measured determinants. More research with multiple follow-up rounds is desired.

Ketazolam (Solatran) an Open Study of Once-a-Day Treatment in Ambulatory Patients with Anxiety

1981 ◽  
Vol 9 (1) ◽  
pp. 69-73 ◽  
Author(s):  
R Deberdt
Keyword(s):  
Open Study ◽  
Rating Scale ◽  
Day Treatment ◽  
Night Time ◽  
Subjective Assessments ◽  
Ambulatory Patients ◽  
Hamilton Anxiety Rating Scale ◽  
Receive Treatment ◽  
To Receive

The efficacy of ketazolam (Solatran®)* in alleviating the symptoms of short-term reactive or neurotic anxiety in thirty-three patients was examined using a single 30 mg night-time dose in an open study. Patients were to receive treatment for up to 1 month and thereafter as necessary for several months. At the follow-up visits, at the end of the first, second and fourth weeks and then at the end of therapy if continued, the clinical condition was assessed by the Hamilton Anxiety Rating Scale and physician's and patients' subjective global assessments. A highly significant improvement was observed after a week's treatment in both somatic and psychic aspects of anxiety. A favourable response as measured by the two subjective assessments was observed in more than 80% of the patients by the third visit. There were two reports of morning tiredness, both dose-related, but no other adverse effects. Only four patients derived no benefit from the treatment.

How soon will the patient with metastasis return for radiosurgery?

2006 ◽  
Vol 105 (Supplement) ◽  
pp. 82-85 ◽  
Author(s):  
Kotaro Nakaya ◽  
Motohiro Hayashi ◽  
Masahiro Izawa ◽  
Taku Ochiai ◽  
Tomokatsu Hori ◽  
...  
Keyword(s):  
Stereotactic Radiosurgery ◽  
Standard Treatment ◽  
Small Cell Lung Carcinoma ◽  
Treatment Options ◽  
Single Session ◽  
Cell Lung Carcinoma ◽  
Almost All ◽  
Medical University ◽  
Median Interval

ObjectStereotactic radiosurgery for brain metastasis has become one of the standard treatment options in recent years. Some patients must undergo repeated stereotactic radiosurgery for new lesions. The authors retrospectively reviewed their data to estimate how soon the patients undergo repeated radiosurgery for new lesions.MethodsBetween October 1999 and March 2006, 1081 patients with brain metastases underwent Gamma Knife surgery (GKS) at Tokyo Women's Medical University. One hundred and forty-nine patients in whom GKS had been performed two or more times were evaluated. There were 68 men and 81 women with a median age of 61 years (range 29–90 years). The authors analyzed data on patient age, number of treated lesions, and period between GKSs. Follow-up imaging was performed in almost all patients every 2 to 3 months after GKS.The number of lesions treated in a single session varied from one to 35. The median interval between GKSs was 26 weeks (range 3–175 weeks) for patients with breast cancer and 23 weeks (range 4–179 weeks) for patients with non–small cell lung carcinoma.Conclusions It would appear that follow-up imaging studies should be obtained every 2 to 3 months after GKS to monitor patients for tumor recurrence.

Results of stereotactic body radiation therapy (SBRT) for T2 lung cancer: Outcomes of longer term follow-up.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. 8542-8542 ◽  
Author(s):  
Stephen Shamp ◽  
Tangel C. Chang ◽  
Tithi Biswas ◽  
Philip Aaron Linden ◽  
Yaron Perry ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Overall Survival ◽  
Cox Regression ◽  
Small Cell Lung Carcinoma ◽  
Combined Modality Therapy ◽  
High Rate ◽  
Tumor Diameter ◽  
Cell Lung Carcinoma ◽  
Cox Regression Analysis

8542 Background: SBRT is a well-established, highly efficacious treatment for T1N0 non-small cell lung carcinoma (NSCLC). Its efficacy in T2N0 cancers is less clear. This is a review of our institutional experience with long-term follow-up. Methods: 45 patients with medically inoperable T2 N0/Nx M0 NSCLC who were treated with definitive SBRT between 2009 and 2013 were analyzed retrospectively. All patients underwent PET/CT staging and fiducial marker placement for image guided therapy with the Cyberknife platform. Radiation dose was 50 Gray in 5 fractions (N = 24), 50 Gray in 4 fractions (N = 11) or 54-60 Gray in 3 fractions (N = 10) delivered over 7 to 14 days. We analyzed overall survival from the date of start of SBRT, and we performed analyses actuarially using Cox regression analysis and Kaplan-Meier survival analysis for comparisons of hazard ratio (HR) among subgroups. Results: 45 patients were studied (median age 74). The 5-year actuarial overall survival was 18.7% (39.3% at 2 years), with most patients dying from lung cancer recurrence/progression outside of the treatment field. Subgroup analyses showed no statistically significant differences with respect to age, gender, histology, nominal radiation prescription dose, tumor diameter or PTV target volume (median PTV 87cc). There was statistically significantly better survival associated with increased maximum biologically effective dose (BED10) of radiation at the center of the tumor (p = 0.03). Conclusions: Unlike the outcomes for T1 NSCLC, our results in T2 NSCLC were disappointing, with a high rate of out-of-field failure and death from lung cancer. We stress the importance of diagnosis and treatment of NSCLC at the T1N0 stage. We suggest that patients with T2N0/Nx NSCLC be considered for SBRT dose intensification and/or combined modality therapy protocols.

Avascular Necrosis in Untreated Patients with Type 1 Gaucher Disease.

Blood ◽  
2009 ◽  
Vol 114 (22) ◽  
pp. 1353-1353
Author(s):  
Pramod K Mistry ◽  
Patrick Deegan ◽  
Ashok Vellodi ◽  
J. Alexander Cole ◽  
Michael Yeh ◽  
...  
Keyword(s):  
Incidence Rate ◽  
Avascular Necrosis ◽  
Gaucher Disease ◽  
Incidence Rates ◽  
Advisory Committees ◽  
Type 1 Gaucher Disease ◽  
Receive Treatment ◽  
To Receive

Abstract Abstract 1353 Poster Board I-375 Objective To determine the incidence of avascular necrosis (AVN) in untreated patients with type 1 Gaucher disease (GD1). Methods All patients with GD1 enrolled in the ICGG Gaucher Registry as of July 2007 were included in this analysis. All GD1 patients who either never received treatment or eventually went on to receive treatment were identified. Follow-up began on each patient's date of earliest reported assessment in the Registry. Among patients who never received treatment, follow-up continued until the last recorded assessment date in the Registry. For patients who eventually went on to receive treatment, follow-up continued until the date of initiation of therapy. Incidence rates (and Poisson exact 95% confidence intervals) of AVN were determined for both groups of patients. AVN was typically ascertained from X-Ray or MRI results. Results As of July 2007, the inclusion criteria were met by 3,497 patients. The incidence rate of AVN among untreated patients was 22.8 per 1,000 person years (95% CI 20.2 to 25.7). Patients with antecedent splenectomy (total or partial) had a higher incidence rate of AVN (46.6 per 1,000 person-years, 95% CI 38.4 to 56.1) compared to patients without a splenectomy (incidence rate 17.0 per 1,000 person-years, 95% CI 14.5 to 19.8). The primary sites where AVN was identified in both groups were the hip and femur. Conclusion This is the first epidemiologic analysis to estimate incidence rates of AVN among untreated patients with GD1. Splenectomy appears to be a risk factor for GD1-associated AVN. Based on the incidence results above and presupposing equal risk distribution, without therapeutic intervention, most patients should theoretically experience at least one episode of AVN at some point in their life. However, because the GD1 population is genotypically and phenotypically heterogeneous, further analyses will attempt to identify characteristics that distinguish untreated patients at high risk of developing AVN from those who are less likely to develop this serious complication. Disclosures Mistry: Genzyme Corporation: Honoraria, Research Funding. Deegan:Genzyme Corporation: Honoraria. Vellodi:Genzyme Corporation: Honoraria, Speakers Bureau. Cole:Genzyme Corporation: Employment. Yeh:Genzyme Corporation: Employment. Weinreb:Genzyme Corporation: Honoraria, Membership on an entity's Board of Directors or advisory committees.

scholarly journals Misdiagnosis of hearing loss due to ear canal collapse: a report of two cases

1996 ◽  
Vol 110 (6) ◽  
pp. 561-566 ◽  
Author(s):  
Cliodna F. O Mahoney ◽  
Linda M. Luxon
Keyword(s):  
Hearing Loss ◽  
External Auditory Meatus ◽  
Noise Induced Hearing Loss ◽  
Ear Canal ◽  
True Nature ◽  
High Frequencies ◽  
Hearing Thresholds ◽  
Retrocochlear Pathology

AbstractCollapse of the external auditory meatus during audiometry can lead to spuriously increased hearing thresholds being obtained, particularly at high frequencies, and may simulate conditions such as noise-induced hearing loss, presbyacusis and retrocochlear pathology. Consequently, inappropriate investigations and management may be undertaken. Two patients with elevated thresholds secondary to ear canal collapse are described. The implications of initially failing to identify the true nature of their ‘hearing losses’ are highlighted and strategies to avoid such pitfalls are discussed.

8. Post-surgical follow-up for non-small cell lung carcinoma: should we change our practice?

2015 ◽  
Vol 41 (11) ◽  
pp. S263-S264 ◽  
Author(s):  
Fahad Fahad ◽  
Mohammed Haris ◽  
Imran Hussain ◽  
Shilajit Ghosh
Keyword(s):  
Lung Carcinoma ◽  
Small Cell Lung Carcinoma ◽  
Small Cell ◽  
Small Cell Lung ◽  
Cell Lung Carcinoma
Sign in / Sign up

Export Citation Format

Share Document